指南与共识头颈部肿瘤放疗

HPV阳性口咽鳞状细胞癌的放射治疗:ASTRO临床实践指南

Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2024-06-18

该指南由ASTRO召集工作组,针对HPV相关口咽鳞癌根治性及术后放疗的5个关键问题给出循证推荐。推荐包括同步顺铂的适应证、术后放疗剂量与观察策略、70 Gy/33–35次及56–60 Gy的剂量方案、优选调强放疗,以及约3个月后PET-CT再评估与颈清扫指征。

要点

  • T3-4和/或>3 cm单个淋巴结或多发淋巴结接受根治性放疗者推荐同步顺铂。
  • 术后切缘阳性或结外扩展推荐同步顺铂放疗;pT3-4、>2个淋巴结或单个>3 cm推荐单纯术后放疗。
  • 根治性同步放化疗推荐7000 cGy/33–35次,术后无切缘阳性及结外扩展推荐5600–6000 cGy。

核心结论

  • HPV相关口咽鳞癌放疗的角色和实践持续演变,本指南基于现有证据为最佳临床实践提供信息。

研究设计与样本

  • ASTRO召集工作组,基于系统文献综述和预定义的共识构建方法与证据质量及推荐强度分级系统制定,针对5个关键问题。
  • 工作组未涉及原发手术与放疗的适应证比较。

主要发现

  • 根治性放疗同步顺铂推荐用于T3-4和/或1个淋巴结>3 cm或多发淋巴结的患者。
  • 对上述类似患者若不适合顺铂,条件性推荐同步西妥昔单抗、卡铂/5-氟尿嘧啶或紫杉类全身治疗。
  • 术后切缘阳性或结外扩展推荐同步顺铂(任一方案)放疗;pT3-4、>2个淋巴结或单个淋巴结>3 cm推荐单纯术后放疗。
  • pT1-2且单个淋巴结≤3 cm无其他危险因素者条件性推荐观察。
  • 根治性放疗同步全身治疗推荐7000 cGy分33–35次;术后无切缘阳性及结外扩展推荐5600–6000 cGy。

关键数值与推荐

  • 所有放疗患者推荐调强放疗而非三维技术,并降低危及器官(包括唾液腺和吞咽结构)剂量。
  • 根治性放疗/放化疗后约3个月推荐PET-CT再评估;有明确残留病变证据推荐颈清扫。
  • PET-CT结果不明确时,推荐颈清扫或重复影像检查。

临床怎么用

  • 根据T分期、淋巴结大小和数目、切缘及结外扩展状态选择根治性同步放化疗、术后同步放化疗、单纯术后放疗或观察。
  • 不适合顺铂者条件性推荐西妥昔单抗、卡铂/5-氟尿嘧啶或紫杉类同步全身治疗。
  • 放疗采用调强技术并保护唾液腺和吞咽结构;根治性同步治疗给予7000 cGy/33–35次,术后无切缘阳性及结外扩展给予5600–6000 cGy。
  • 根治性放疗/放化疗后约3个月行PET-CT再评估,明确残留者行颈清扫,不明确者行颈清扫或重复影像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Human Papilloma Virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is a distinct disease from other head and neck tumors. This guideline provides evidence-based recommendations on the critical decisions in its curative treatment, including both definitive and postoperative radiation therapy (RT) management. METHODS: ASTRO convened a task force to address 5 key questions on the use of RT for management of HPV-associated OPSCC. These questions included indications for definitive and postoperative RT and chemoradiation; dose-fractionation regimens and treatment volumes; preferred RT techniques and normal tissue considerations; and posttreatment management decisions. The task force did not address indications for primary surgery versus RT. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS: Concurrent cisplatin is recommended for patients receiving definitive RT with T3-4 disease and/or 1 node >3 cm, or multiple nodes. For similar patients who are ineligible for cisplatin, concurrent cetuximab, carboplatin/5-fluorouracil, or taxane-based systemic therapy are conditionally recommended. In the postoperative setting, RT with concurrent cisplatin (either schedule) is recommended for positive surgical margins or extranodal extension. Postoperative RT alone is recommended for pT3-4 disease, >2 nodes, or a single node >3 cm. Observation is conditionally recommended for pT1-2 disease and a single node ≤3 cm without other risk factors. For patients treated with definitive RT with concurrent systemic therapy, 7000 cGy in 33 to 35 fractions is recommended, and for patients receiving postoperative RT without positive surgical margins and extranodal extension, 5600 to 6000 cGy is recommended. For all patients receiving RT, intensity modulated RT over 3-dimensional techniques with reduction in dose to critical organs at risk (including salivary and swallowing structures) is recommended. Reassessment with positron emission tomography-computed tomography is recommended approximately 3 months after definitive RT/chemoradiation, and neck dissection is recommended for convincing evidence of residual disease; for equivocal positron emission tomography-computed tomography findings, either neck dissection or repeat imaging is recommended. CONCLUSIONS: The role and practice of RT continues to evolve for HPV-associated OPSCC, and these guidelines inform best clinical practice based on the available evidence.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Margalit DN, Anker CJ, Aristophanous M, et al. Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2024. PMID: 39078350. doi:10.1016/j.prro.2024.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。